Skip to main content

Harry Paul Erba CV

Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
DUMC Box 3961, Durham, NC 27710
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
CV

Overview


I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine.  I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies.  I am also the Chair of the SWOG Leukemia Committee.  I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia.  Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.

Office Hours


Office hours:
Monday, 8 a.m. to 12 p.m.
Tuesday, 8 a.m. to 5 p.m.
Wednesday, 8 a.m. to 12 p.m.
Friday, 1 p.m. to 5 p.m.

Current Appointments & Affiliations


Professor of Medicine · 2023 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine
Member of the Duke Cancer Institute · 2018 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia.

Conference medRxiv · January 26, 2026 Post-treatment measurable residual disease (MRD) in acute myeloid leukemia (AML) patients is associated with adverse clinical outcomes. Validated molecular methods for AML MRD are preferable to flow cytometry assays but are not available for all patients. ... Full text Link to item Cite

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.

Journal Article Blood Neoplasia · November 2025 Preclinical data suggest CPX-351, approved for patients with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes, may exhibit synergy with targeted agents, suggesting a rationale for combining targeted ag ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


Stanford University, School of Medicine · 1988 M.D.
Stanford University · 1988 Ph.D.